North America Pharmaceutical Contract Development and Manufacturing Market (2025-2032)
The North America Pharmaceutical Contract Development and Manufacturing Market is expected to reach $105.42 billion by 2032 at a CAGR of 7.1% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 150
- Format
- PDF + Excel
- Report ID
- MRHC - 1041066
- Base year
- 2022
- 2032 · FORECAST
- $105.4B
- 2032
- $105.4B
- CAGR 2025–2032
- 7.1%
2022–2024 baseline · 2025–2032 forecast at 7.1% CAGR · hover a bar for the value
Key highlights
The North America Pharmaceutical Contract Development and Manufacturing Market is expected to reach $105.42 billion by 2032 at a CAGR of 7.1% from 2025 to 2032.
The pharmaceutical manufacturing services segment is expected to account for the largest share of the market.
The large pharmaceutical companies segment is expected to account for the largest share of the market.
The U.S. is expected to register the highest CAGR during the forecast period. Factors such as drug shortages due to the emergence of the COVID-19 pandemic, the presence of large pharmaceutical and biotechnology manufacturers, biopharmaceutical R&D funding, and rising demand for cell and gene therapies in the U.S.
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | ~150 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2022 |
| CAGR | 7.1% |
| Estimated Market Size (Value) | $105.42 billion by 2032 |
| Segments Covered | by Type · Pharmaceutical Manufacturing Services · Active Pharmaceutical Ingredient (API) Manufacturing Services · Finished Dosage Forms (FDF) Manufacturing Services · Parenteral/Injectable Manufacturing Services · Tablet Manufacturing Services · Capsule Manufacturing Services · Oral Liquid Manufacturing Services · Other Formulations · Drug Development Services · Biologics Manufacturing Services · Active Pharmaceutical Ingredient (API) Manufacturing Services · Finished Dosage Forms (FDF) Manufacturing Services · by End User · Large Pharmaceutical Companies · Small & Mid-Size Pharmaceutical Companies · Generic Pharmaceutical Companies · by Country · U.S. · Canada |
| Countries Covered | North America (U.S., Canada) |
| Key Companies | Thermo Fisher Scientific Inc. (U.S.), Catalent, Inc. (U.S.), C.H. Boehringer Sohn AG & CO. KG. (Germany), Synoes Health, Inc. (U.S.), Curia Global, Inc. (U.S.), Cambrex Corporation (U.S.), FUJIFILM Diosynth Biotechnology (U.S.), Samsung Biologics (South Korea), Siegfried Holding AG (Switzerland), Aenova Group (Germany), WuXi Biologics (China), and Vetter Pharma International GmbH (Germany). |
Report overview
Segments covered: end user. Regions: North America.
Pharmaceutical contract development and manufacturing organizations (CDMOs) partner with pharmaceutical companies and offer contract-based manufacturing and drug development services. CDMOs handle everything from pre-formulation and formulation development to clinical trials and manufacturing. Pharmaceutical companies opt for CDMOs because of the benefits such as reduced labor, cost, high product quality, faster time, and resource savings.
The growth of the North America pharmaceutical contract development and manufacturing market is attributed to the complex manufacturing requirements of the pharmaceutical industry, manufacturers’ growing inclination towards the use of cutting-edge technologies, patent expiration, increasing investments in pharmaceutical R&D, and the rising demand for generic medicines & biologics. However, the lack of skilled professionals is challenging the growth of this market. In addition, growing consolidation among CDMO market players and virtual business models are the industry trends in the market.
Report infographic
Market dynamics
2 factors across 2 forcesComplex Manufacturing Requirements of the Pharmaceutical Industry is Driving the Demand for Pharmaceutical Contract Development and Manufacturing Organizations
The pharmaceutical industry is largely driven by scientific discovery, development, and toxicological and clinical experience. Pharmaceutical manufacturing operations may be categorized as primary production of bulk drug substances (APIs) and manufacturing of dosage form products (formulations).
In addition to the complexity of the pharmaceutical manufacturing process, many countries globally have specific legal protections for proprietary drugs and manufacturing processes, known as intellectual property rights. When legal protections are limited or nonexistent, some companies specialize in manufacturing and marketing generic drugs. The pharmaceutical industry requires large capital investments due to the high expenses associated with R&D, regulatory approvals, manufacturing, quality assurance & control, marketing, and sales.
U.S. and Canada have extensive government regulations affecting the development and approval of drugs for commercial sale. These countries have strict requirements for good manufacturing practices to ensure the integrity of drug manufacturing operations and pharmaceutical products' quality, safety, and efficacy. These challenges have led pharmaceutical companies to partner with contract manufacturing and development organizations to develop and manufacture pharmaceuticals and biologics, driving the growth of the pharmaceutical contract development and manufacturing market.
Table of contents
10 chapters · 76 sections · 150 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Type | Pharmaceutical Manufacturing Services | — |
| By End User | Large Pharmaceutical Companies | — |
By Type
- The pharmaceutical manufacturing services segment is expected to account for the largest share of the market.
- The large of this segment is attributed to factors such as the growing need to reduce manufacturing costs in the pharmaceutical industry, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.
- According to the U.S. FDA, as of 2022, it is estimated that 91% of all prescriptions in the United States are filled as generic drugs, with more than 32,000 generic drugs approved.
By End User
- The large pharmaceutical companies segment is expected to account for the largest share of the market.
- The large market share of this segment is attributed to the increasing demand from businesses worldwide, the increasing need for state-of-the-art processes and production technologies, and the continued efforts of pharmaceutical companies to reduce production costs.
- Additionally, with the increasing burden of diseases, the demand for drugs is increasing.
- Thus, to tackle the high demand, pharmaceutical companies are collaborating or partnering with CDMOs.
- For instance: In May 2021, Siegfried Holdings AG (Switzerland) signed an agreement with Novavax, Inc. (U.S.) to manufacture and supply Novavax's protein-based COVID-19 Vaccine.
- Under this agreement, Siegfried served as a non-exclusive supplier for the aseptic fill and finish of Novavax's COVID-19 vaccine NVX-CoV2373.
Geographic analysis
North America
Fastest growthThe U.S. is expected to register the highest CAGR during the forecast period. Factors such as drug shortages due to the emergence of the COVID-19 pandemic, the presence of large pharmaceutical and biotechnology manufacturers, biopharmaceutical R&D funding, and rising demand for cell and gene therapies in the U.S. drive the pharmaceutical contract development and manufacturing market. Growing demand for biopharmaceuticals and supportive initiatives for their adoption resulted in expanding biopharmaceutical manufacturing facilities in the U.S. For instance, in April 2022, FUJIFILM Diosynth Biotechnologies (U.S.) announced to build BioProcess Innovation Center in Research Triangle Park (U.S.). The facility will have analytical instrumentation, high throughput bioprocessing equipment, and automation technologies. Also, in March 2022, Amgen, Inc. (U.S.) announced the establishment of a biomanufacturing facility in North Carolina (U.S.). The facility is expected to be operational by 2025. The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players operating in the North America pharmaceutical contract development and manufacturing market are Thermo Fisher Scientific Inc. (U.S.), Catalent, Inc. (U.S.), C.H. Boehringer Sohn AG & CO. KG. (Germany), Synoes Health, Inc. (U.S.), Curia Global, Inc. (U.S.), Cambrex Corporation (U.S.), FUJIFILM Diosynth Biotechnology (U.S.), Samsung Biologics (South Korea), Siegfried Holding AG (Switzerland), Aenova Group (Germany), WuXi Biologics (China), and Vetter Pharma International GmbH (Germany). U.S.: Fastest Growing Market North America Pharmaceutical Contract Development and Manufacturing: Key Players
Competitive landscape
- Thermo Fisher Scientific Inc. (U.S.)
- Catalent, Inc. (U.S.)
- C.H. Boehringer Sohn AG & CO. KG · Germany
- Synoes Health, Inc. (U.S.)
- Curia Global, Inc. (U.S.)
- Cambrex Corporation (U.S.)
- FUJIFILM Diosynth Biotechnology (U.S.)
- Samsung Biologics · South Korea
- Siegfried Holding AG · Switzerland
- Aenova Group · Germany
- WuXi Biologics · China
- Vetter Pharma International GmbH · Germany
Frequently asked questions
The North America pharmaceutical contract development and manufacturing market studies different types of services, such as pharmaceutical manufacturing services, drug development services, and biologics manufacturing services used by end users. The North America pharmaceutical contract development and manufacturing market studied in this report involve the analysis of various segments at country levels.
Cite this report
Meticulous Research. (2025). North America Pharmaceutical Contract Development and Manufacturing Market - Opportunity Analysis and Industry Forecasts (2025-2032) (Report No. MRHC - 1041066). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/north-america-pharmaceutical-contract-development-and-manufacturing-market-5749